Entry

D01253                      Drug

Name

Clobazam (JAN/USAN/INN);
Mystan (TN);
Onfi (TN)

Product

SYMPAZAN (Aquestive Therapeutics), ONFI (Lundbeck Pharmaceuticals LLC)

Generic

CLOBAZAM (American Health Packaging), CLOBAZAM (Amneal Pharmaceuticals NY LLC), CLOBAZAM (Amneal Pharmaceuticals NY LLC), CLOBAZAM (Ascend Laboratories), CLOBAZAM (Ascend Laboratories), CLOBAZAM (Aurobindo Pharma Limited), CLOBAZAM (Bionpharma), CLOBAZAM (Bionpharma), CLOBAZAM (Breckenridge Pharmaceutical), CLOBAZAM (CELLTRION USA), CLOBAZAM (Cadila Healthcare Limited), CLOBAZAM (Camber Pharmaceuticals), CLOBAZAM (Camber Pharmaceuticals), CLOBAZAM (Chartwell RX), CLOBAZAM (Hikma Pharmaceuticals USA), CLOBAZAM (Lannett Company), CLOBAZAM (Lannett Company), CLOBAZAM (Lupin Pharmaceuticals), CLOBAZAM (Lupin Pharmaceuticals), CLOBAZAM (MSN LABORATORIES PRIVATE LIMITED), CLOBAZAM (Micro Labs Limited), CLOBAZAM (Mylan Pharmaceuticals), CLOBAZAM (NorthStar RxLLC), CLOBAZAM (NorthStar RxLLC), CLOBAZAM (Novadoz Pharmaceuticals LLC), CLOBAZAM (Sandoz), CLOBAZAM (Taro Pharmaceuticals U.S.A.), CLOBAZAM (Taro Pharmaceuticals U.S.A.), CLOBAZAM (Taro Pharmaceuticals U.S.A.), CLOBAZAM (Upsher-Smith Laboratories), CLOBAZAM (Upsher-Smith Laboratories), CLOBAZAM (VistaPharm), CLOBAZAM (West-Ward Pharmaceuticals Corp.), CLOBAZAM (Zydus Pharmaceuticals (USA))

Formula

C16H13ClN2O2

Exact mass

300.0666

Mol weight

300.7396

Structure

Simcomp

Class

Neuropsychiatric agent
DG01567  GABA-A receptor agonist
DG01914  Anxiolytics, benzodiazepine derivatives
DG03199  Antiepileptic agent
  DG02036  Benzodiazepine derivative, antiepileptic
Metabolizing enzyme substrate
DG01639  CYP2C19 substrate
DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate

Remark

Therapeutic category:

1139

ATC code:

N05BA09

Product:

D01253<JP/US>

Efficacy

Anticonvulsant, Minor tranquilizer

Disease

Lennox-Gastaut syndrome [DS:H01813]

Comment

Benzodiazepine derivative

Target

GABR [HSA:2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 55879] [KO:K05175 K05181 K05184 K05185 K05186 K05189 K05192]

Pathway

hsa04080

Neuroactive ligand-receptor interaction

hsa04727

GABAergic synapse

Metabolism

Enzyme: CYP3A4 [HSA:1576], CYP2C19 [HSA:1557]

Interaction

Structure map

map07033

Anticonvulsants

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
  N05 PSYCHOLEPTICS
   N05B ANXIOLYTICS
    N05BA Benzodiazepine derivatives
     N05BA09 Clobazam
      D01253  Clobazam (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Anticonvulsants
  Gamma-aminobutyric Acid (GABA) Augmenting Agents
   Benzodiazepines
    Clobazam
     D01253  Clobazam (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1  Agents affecting nervous system and sensory organs
  11  Agents affecting central nervous system
   113  Antiepileptics
    1139  Others
     D01253  Clobazam (JAN/USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
  DG01567  GABA-A receptor agonist
   D01253  Clobazam
  DG01914  Anxiolytics, benzodiazepine derivatives
   D01253  Clobazam
  DG03199  Antiepileptic agent
   DG02036  Benzodiazepine derivative, antiepileptic
    D01253  Clobazam
Metabolizing enzyme substrate
  DG01639  CYP2C19 substrate
   D01253  Clobazam
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D01253  Clobazam
Drug classes [BR:br08332]
Neuropsychiatric agent
  DG03199  Antiepileptic agent
   D01253  Clobazam
Target-based classification of drugs [BR:br08310]
Ion channels
  Ligand-gated ion channels
   GABA (ionotropic)
    GABR
     D01253  Clobazam (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D01253
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D01253
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D01253
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D01253
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
  D01253

Other DBs

CAS:	22316-47-8

PubChem:

7848316

ChEBI:

31413

LigandBox:

D01253

NIKKAJI:

J11.411A

KCF data

ATOM        21
            1   C5x C    20.8440  -16.6025
            2   C1x C    21.7290  -15.5177
            3   C5x C    21.4335  -14.1745
            4   N1y N    20.1974  -13.5636
            5   N1y N    19.4423  -16.6153
            6   C8y C    18.9128  -14.1417
            7   C8y C    18.5788  -15.4592
            8   C8x C    17.2356  -15.7546
            9   C8y C    16.2236  -14.8026
            10  C8x C    16.5605  -13.4152
            11  C8x C    17.9036  -13.1197
            12  X   Cl   14.8804  -15.0980
            13  O5x O    21.3522  -17.8843
            14  C8y C    18.7672  -17.7087
            15  C1a C    20.3245  -12.1676
            16  O5x O    22.5198  -13.3081
            17  C8x C    17.3603  -17.7403
            18  C8x C    16.6880  -18.9683
            19  C8x C    17.4154  -20.1645
            20  C8x C    18.8222  -20.1326
            21  C8x C    19.4945  -18.9046
BOND        23
            1     3   4 1
            2     1   5 1
            3     4   6 1
            4     2   3 1
            5     5   7 1
            6     1   2 1
            7     6   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11   10  11 1
            12    6  11 2
            13    9  12 1
            14    1  13 2
            15    5  14 1
            16    4  15 1
            17    3  16 2
            18   14  17 2
            19   17  18 1
            20   18  19 2
            21   19  20 1
            22   20  21 2
            23   14  21 1